Wolfgang Kern

发表

“STATE-OF-THE-ART” COKING TECHNOLOGIES. CHALLENGING EMISSIONS AT THE SERVICE OF THE ENVIRONMENT: A PRACTICAL BRAZILIAN EXAMPLE

Antonio Esposito, Jan Krull, Wolfgang Kern, 2014 .

Integration of clinical and genetic information - from patient data to gene expression analysis

Martin Dugas, Torsten Haferlach, Wolfgang Kern, 2002, Silico Biol..

Die neuen Vier-und Sechszylinder-Ottomotoren von BMW mit Schichtbrennverfahren

Andreas Witt, Erik Schünemann, Wolfgang Kern, 2007 .

Dark-matter matters: Discriminating subtle blood cancers using the darkest DNA

Kahn Rhrissorrakrai, Torsten Haferlach, Wolfgang Kern, 2019, PLoS Comput. Biol..

Kontextverarbeitung auf Basis von RFID bei der mobilen Wartung von komplexen Produkten

Heinz-Josef Eikerling, Wolfgang Kern, Matthias Benesch, 2007 .

Impact of integrating clinical and genetic information

Martin Dugas, Torsten Haferlach, Wolfgang Kern, 2001, German Conference on Bioinformatics.

Méthode pour distinguer les différents prognostics de la LMA

Torsten Haferlach, Wolfgang Kern, Claudia Schoch, 2003 .

Open Source Software-Release: Ein Ratgeber für die Veröffentlichung von Software unter dem Open Source-Status

Ulrich Bretschneider, Wolfgang Kern, Heidi Hohensohn, 2004 .

Knowledge transfer to enhance the performance of deep learning models for automated classification of B cell neoplasms

Torsten Haferlach, Wolfgang Kern, Peter M. Krawitz, 2021, Patterns.

The Use of Unique Molecular Identifiers (UMIs) Strongly Improves Sequencing Detection Limits Allowing Earlier Detection of Small TP53 Mutated Clones in Leukemias

Torsten Haferlach, Wolfgang Kern, Claudia Haferlach, 2016 .

Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology.

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2011, The Journal of molecular diagnostics : JMD.

Modern diagnostics in acute leukemias.

Torsten Haferlach, Wolfgang Kern, Claudia Schoch, 2005, Critical reviews in oncology/hematology.

Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia

Christoph Schmid, Torsten Haferlach, Wolfgang Kern, 2016, Haematologica.

Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1).

Paola Fazi, Marco Vignetti, Hans-Ulrich Klein, 2010, Blood.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Torsten Haferlach, Claude Preudhomme, Wolfgang Kern, 2018, Blood.

First Results of a 31-Gene Panel Targeted to Investigate Myeloid Malignancies by Next-Generation Amplicon Deep-Sequencing

Torsten Haferlach, Wolfgang Kern, Susanne Schnittger, 2012 .

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

Wolfgang Kern, Jean Feuillard, Luca Malcovati, 2009, Haematologica.

Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene

Torsten Haferlach, Wolfgang Kern, Susanne Schnittger, 2014, British journal of haematology.

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

Martin Dugas, Torsten Haferlach, Wolfgang Kern, 2002 .

The role of multiparameter flow cytometry for disease monitoring in AML.

Torsten Haferlach, Wolfgang Kern, Susanne Schnittger, 2010, Best practice & research. Clinical haematology.

High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias

Wolfgang Kern, Michael Unterhalt, Wolfgang Hiddemann, 1997, Cancer.

Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1.

Martin Dugas, Hans-Ulrich Klein, Torsten Haferlach, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An Artificial Intelligence (AI) Approach for Automated Flow Cytometric Diagnosis of B-Cell Lymphoma

Torsten Haferlach, Wolfgang Kern, Peter M. Krawitz, 2018, Blood.

Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile

Torsten Haferlach, Wolfgang Kern, Wolfgang Hiddemann, 2005, Genes, chromosomes & cancer.

Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome

Torsten Haferlach, Wolfgang Kern, Susanne Schnittger, 2014, Genes, chromosomes & cancer.